1 Introduction
2 Materials and methods
2.1 Study design
2.2 Blood collection and processing
2.3 Immunofluorescent staining
2.4 Detection and classification of rare events
2.5 Statistical analysis
3 Results
3.1 Patient demographics
Variables | Category | Value n (%) |
---|---|---|
Age | Range: 30–81 Median: 61 | |
Gender | Female | 8 (80%) |
Male | 2 (20%) | |
Race | Caucasian Non-Hispanic | 3 (30%) |
Caucasian Hispanic | 5 (50%) | |
African American | 2 (20%) | |
Cancer history | Yes | 1 (10%) |
No | 9 (90%) | |
Family history | Yes | 2 (20%) |
No | 8 (80%) | |
Smoking | Yes | 3 (30%) |
No | 6 (60%) | |
N/A | 1 (10%) | |
Disease stage | IIIA | 1 (10%) |
IIIB | 1 (10%) | |
IV* | 8 (80%) | |
Clinical T staging | T1B | 3 (30%) |
T2A | 1 (10%) | |
T3 | 3 (30%) | |
T4 | 2 (20%) | |
N/A | 1 (10%) | |
Clinical N staging | N0 | 3 (30%) |
N2 | 2 (20%) | |
N3 | 4 (40%) | |
N/A | 1 (10%) | |
Clinical M staging | M0 | 3 (30%) |
M1A | 1 (10%) | |
M1B | 2 (20%) | |
M1C | 3 (30%) | |
N/A | 1 (10%) | |
Histological subtype | Adenocarcinoma | 9 (90%) |
Adenosquamous carcinoma | 1 (10%) | |
Death | Yes | 4 (40%) |
N/A | 6 (60%) | |
Prior Therapy | Carboplatin and Taxol | 1 (10%) |
Carboplatin and Pemetrexed | 1 (10%) | |
Pemetrexed | 1 (10%) | |
None | 7 (70%) |